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Introduction
The human face and facial transplantation has long 
captured the interest and imagination of scientists, 
the media and the lay public. This is not surprising since our faces
are unique parts of our anatomy that like no other we associate
with special qualities that make us uniquely human. Our face is
much more than the anatomical location where our olfactory, 
auditory and visual organs are situated. We use facial expressions
to communicate with the world around us and our face is the win-
dow through which others see and come to know us. We commu-
nicate these feelings in our spoken language with terms like “let’s
face it”, “face to face”, “maintain face” and “face value”. It is this
great importance we attach to our face that makes facial 
disfigurement such a devastating condition. Of all the physical
handicaps, none is more socially devastating than facial 
disfigurement. In a large number of cases facial disfigurement
leads to depression, social isolation, and even the risk of 
suicide 1,2.  Rather than the sympathy or pity evoked by an ampu-
tated limb, a crutch, or a wheelchair, facial disfigurement elicits
anxiety, fear and a wish to remove it from one’s sight.3, 4 In the
words of a patient suffering with facial disfigurement: “I’ve spent
fifteen years being treated for nothing other than looking different
from everyone else. It was the pain from that, from feeling ugly,
that I’d always viewed as the great tragedy in my life. The fact that
I had cancer seemed minor in comparison.”5
Facial transplantation could provide an excellent alternative to
current treatments for facial disfigurement caused by burns, 
trauma, cancer extirpation or congenital birth defects. As the 
introduction of solid organ transplantation provided an effective
treatment for end stage organ failure and in doing so 
revolutionized the field of transplant immunology, so could 
facial transplantation revolutionize the field of reconstructive 
surgery for severe facial disfigurement.  The introduction of organ
transplantation into the clinical arena brought with it many 
technical, immunological and ethical issues that heretofore had
never been seen by the scientific and lay communities. This is also
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the case with facial transplantation. The purpose of this editorial is
to inform the reader of the major technical, immunological and
ethical issues surrounding facial transplantation and to elicit 
professional discussion from the surgical community.
Technical Issues
Current methods of treating facial disfigurement consist of 
repairing or reattaching the original tissues, transferring 
autologous tissues from another part of the body, and using 
prosthetic materials to restore facial appearance and function.  By
far the best outcomes are achieved when the original tissues can be
salvaged and used to reconstruct the defect. In cases when this is
not possible either because the trauma or disease causing the loss
destroyed the tissue beyond use (major crush injuries, 
severe burns, tumor invasion) or because the original tissues never
existed in the first place (congenital birth defects) reconstructive
surgeons must resort to autologous tissue transfers or prosthetic
materials. In the former instance, skin grafts are used for simple
wound coverage while skin and composite tissue flaps are used 
to reconstruct complex tissue defects. In the latter circumstance 
prosthetic materials are specially designed to camouflage 
the defect. 
Over the past 20 years current treatment options have experienced
many advances: Skin grafting has benefited from new grafting
methods and new techniques used to care for the skin once it is
transferred.6 Techniques that enable the use of bioengineered skin
products have greatly increased treatment options and 
improved outcomes.7 Skin and composite tissue flap transfer 
techniques have revolutionized the field of reconstructive facial
surgery.  By enabling surgeons to reconnect very small blood 
vessels and nerves, advances in microsurgical techniques and
instrumentation have made it possible to replant8, 9 and transplant
tissues from any part of the body to reconstruct complex facial 
tissue deficits. 9a, 10, 11, 12, 13 Prosthetic materials are devices made of
a variety of different synthetic materials. New materials have
improved these devices with improved match (color and texture)
to the tissues adjacent to the defect they cover.14, 15
In spite of these advances, current treatments for severe facial 
disfigurement are still far from ideal. While the methods that use
autologous tissue do a good job of “filling in” the defect, 
the absence of facial tissues results in little to no functional 
recovery, the aesthetic outcomes are poor at best and the donor site
from where the tissues are taken often present major problems.
In some severely injured patients more that 100 procedures over
periods of 10 to 20 years have been required. In these complex
cases this extended series of reconstructions are fraught with 
complications, frequently fail to achieve the intended result, and
often worsen the deformity. Treatments using prosthetic materials
are excellent for giving the patient a normal static aesthetic
appearance but they provide no functional or dynamic return, 
robbing the patient of his or her ability to communicate with facial
expressions.
Facial transplantation would make it possible to use healthy
facial tissues (identical to the recipients’original tissues) to 
reconstruct the defect and thus provide better outcomes and 
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eliminate many of the problems associated with current 
treatments. Facial transplantation would consist of removing
facial tissues from a brain dead donor (solid organ donor) and 
transplanting it to a recipient to reconstruct the facial defect. 
The severely scared and fibrotic tissue on the recipient’s face
would be  removed and replaced with anatomically and 
functionally normal tissues, which over a period of 1-2 years
would be expected to regain significant facial nerve function 
and animation. 
Donor tissue procurement: When the donor tissue is located and
confirmed to meet the pre-established inclusion criteria the 
recipient will be notified, brought to the hospital and prepared for
surgery. At the same time members of the surgical team will
accompany the solid organ procurement team to retrieve the donor 
tissue. The technical details of retrieving the donor facial tissues
are challenging and technique dependent. It is expected that in
most cases all of the soft tissue down to the bone will be needed
to reconstruct a severely disfigured face. At its most basic, the
donor facial tissue will be matched to and patterned from the
defect defined by the recipient’s deformity.  This segment of tissue
will include skin, subcutaneous tissue, muscle, and the arteries,
veins and nerves necessary to satisfactorily perfuse and innervate
the facial musculature of the transplanted facial tissue. 
Facial tissue implantation: While surgical implantation will take
many hours, the first surgical priority will be to revascularize the
facial tissue retrieved from the donor so as to minimize the
ischemia time. It is important to note that the tissues that will be
transplanted in this procedure (skin, subcutaneous tissue, muscle)
can withstand relatively long periods of ischemia14 therefore it is
not anticipated that this will present a problem. If the defect
requires that a full face be transferred, it is expected that four 
arteries and four veins would be reattached and as many as 
twenty facial motor nerve branches and major sensory nerves
would be repaired.
In the event the full face is not required to reconstruct the defect,
proportionately fewer artery, vein and nerve repairs will be 
necessary. While reattaching multiple vessels to provide perfusion
is the best case scenario, and will most likely be possible in facial
transplantation procedures, it is well known that, due to its rich
blood supply, face or scalp tissue can survive on only one good
perfusing vessel.17 Once the vessels are reattached and the blood
supply is restored to the transplanted tissue, the remainder of the
reconstruction - reattaching the many delicate structures and
nerves can be carried out in a methodical and unhurried fashion
and could take as long as 8 to 16 hours to complete. 
If it becomes necessary to remove the transplanted facial tissue,
due to technical complications (thrombosis of the reattached 
vessels) or due to rejection (because the immunosuppressive drugs
must be discontinued), either another donor would be identified
for a second transplantation or the patient’s treatment protocol
would revert to conventional reconstructive methods (grafts, flaps,
etc...) depending on the cause of failure.
In many respects current methods that repair and reattach 
damaged tissues or that remove, transfer and reconfigure 
autologous tissues to reconstruct facial deformities are more 
technically challenging than transplanting healthy facial tissues
from a donor. The technical expertise and techniques needed to
transplant human facial tissue are common practice and are 
performed daily in most centers where complex facial 
reconstructive procedures are performed.  These methods have
been developed and improved over the years and are the basis for
current facial reconstructive and aesthetic techniques. 
Immunological Issues
From an immunological standpoint, since the face and the hand
contain mostly the same tissues it is reasonable to assume that the
same immunosuppressive regimen found to be effective in human
hand transplants should also work in face transplantation.  In 1997
experiments in a large animal model18 demonstrated that a 
new immunosuppressive drug regimen widely used in organ
transplantation (tacrolimus/MMF/prednisone) successfully pre-
vented composite tissue allograft rejection, while causing minimal
systemic toxicity.19, 20 Based on these experiments in 1998 and
1999 teams in Lyon (France), Louisville (USA) and Guangzhou
(China) performed the first 4 human hand transplants using this
same drug regimen.21, 22, 23 The most common complications associ-
ated with the use of immunosuppressants include increased inci-
dence of infections, malignancies, and end-organ toxicity.  In the
case of tacrolimus/MMF/prednisone combination therapy (the
drug regimen that would most likely be used in facial transplanta-
tion), the incidence of these complications are as follows:
Infections: The incidence of opportunistic infections, including
CMV, reported in kidney transplant recipients using tacrolimus
and MMF range from 8.4% to 31%.24, 25 When this complication
occurs, the initial treatment usually consists of the appropriate
antibiotic, antifungal, or antiviral agent.  In rare cases it is 
necessary to lower the level of immunosuppression, or even to halt
immunosuppression altogether.
Malignancies: In kidney transplant recipients (receiving similar
doses of MMF at 2g/day as would facial transplant recipients)
there exists a 1.2% incidence of post transplant lymphoprolifera-
tive disease (PTLD) and 11.1% incidence of non-melanoma skin
carcinoma.26, 27, 28 In the case of heart, lung, or liver transplants, 
the only resources for treatment of these malignancies are surgery,
irradiation, or chemotherapy.  Due to the life-saving nature of
these transplants, omission of immunosuppression would lead 
to rejection and consequently death.  In the case of kidney 
transplantation, however, in addition to the appropriate oncologic
treatment, immunosuppression is usually halted to restore 
the patient’s immune responsiveness against the tumor. 
This would also be possible for facial transplantation, where the 
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non-life saving nature of the transplant would allow 
the immunosuppressive treatment to be stopped without causing
death.
End-organ toxicity: In solid organ recipients, tacrolimus has been
reported to be associated with end-organ toxicity presenting itself
in the form of post-transplant diabetes mellitus in 7 to 11.9%. 
Of these approximately 2/3 are able to discontinue insulin within
12 months after transplant.29 Tacrolimus is also nephrotoxic, 
as evidenced by increased blood creatinine levels in 
approximately 20% of the recipients using this drug.  Since organ
toxicity is relatively drug-specific, substitution with different
drugs often offers a solution in these cases.  Combining tacrolimus
with MMF makes it possible to reduce the tacrolimus doses and
thus diminishes nephrotoxicity while maintaining adequate
immunosuppression.
It could be argued that in terms of immunosuppression-related
end-organ toxicity, facial transplant recipients will be at an 
advantage over solid organ recipients. This advantage stems from
the fact that by the time solid organ recipients receive their donor
organ, they have often already experienced multiple organ 
problems from their underlying chronic disease.  When they
receive their transplanted organ, the immunosuppressive drugs
they must take often further damage their already debilitated
organs.  In the case of facial transplant recipients, serious 
underlying chronic disease would exclude the patient from 
transplantation and therefore their organs should be healthy.
Therefore, it is reasonable to expect less end-organ toxicity from
the immunosuppressive drugs in facial transplant recipients when
compared with solid organ recipients. While it is not possible to
predict long term rejection in facial transplantation one can draw
some conclusions from preliminary findings in the more than 
20 human hand transplants performed to date worldwide. With the
exception of the first hand recipient (Lyon, France) who requested
that his transplanted hand be removed (due to immunotherapy
noncompliance and rejection) two years and four months post-
transplant30 all other cases have been reported to be successful.
Functional and aesthetic recovery, for as long as 5 years 
post-transplantation, has been described as good and 
immunosuppressant related complications have been minimal.
This success in animal research19, 20 followed by the success of over
20 human hand transplants documents the feasibility of this 
concept and strongly suggests that from an immunological stand-
point facial tissue transplantation would also be successful.
Ethical Issues
As in all medical advances there are many ethical issues 
surrounding facial transplantation. For a detailed list of these 
ethical issues the reader is directed to the recent publication pro-
duced by the Royal College of Surgeons; Facial Transplantation;
Working Party report.31 It is beyond the scope of this editorial to
address each individual ethical issue associated with facial 
transplantation. Instead, here we will discuss the risk vs. 
benefit equation associated with facial transplantation and provide
a list of ethical guidelines our team is following as we move facial
transplantation research into the clinical arena. 
The Risk vs. Benefit equation. The question “do the benefits 
of facial transplantation justify the risks posed by the 
immunosuppressive drugs required to prevent rejection?” is at the
center of the ethical issues surrounding facial transplantation.
While the risks of immunosuppression are generally accepted for
“life-saving” organ transplantation procedures, these same risks
are questioned when it comes to “non-life saving” or “quality-of-
life improving” procedures like face transplantation. 
Risks: Since everyone’s understanding of risk is different, 
to assess the amount of risk different individuals are willing to
accept to receive the benefits of facial transplantation our team
developed a questionnaire-based study to assess this situation.32
Our initial findings from over 250 individuals in 
4 populations (1. healthy normal subjects, 2. upper extremity
amputees, 3. kidney transplant recipients and 4. individuals with
facial disfigurements) questioned indicate that they would accept
significantly more risk to receive a face transplant than a single
hand, double hand, larynx, foot or even a kidney transplant.33
This latter point is interesting since kidney transplantation is a 
universally accepted treatment for which the risk vs. benefit ratio
is largely unquestioned. 
Benefits: Benefits associated with facial transplantation can 
be separated into functional, aesthetic and psychological. 
The relative importance of these three types of benefits is 
important when assessing risk vs. benefits in transplant candidates
and will vary from patient to patient.35 For example a hand 
transplant provides predominantly functional and, to a lesser
degree, aesthetic benefits.  The combination of these 2 benefits
contributes to the psychological benefit derived from this 
procedure.  This was evidenced in Louisville’s 1st hand transplant 
recipient, in his repeated statements that his transplanted hand
gives him a sense of being ‘whole’ and ‘complete’.35 In the case
of facial transplantation the functional benefits would depend on
the deformity and could include such gains as restoration of eye
blink, chewing, swallowing, oral continence, speaking, 
facial sensation and facial expressions. The aesthetic benefits
would improve the patient’s body image and sense of self. 
While it could be argued which of these benefits would be more 
important, there would be no argument that both would have a
major impact on the patient’s psychological benefits.
Other considerations: The availability of donor tissue in facial
transplantation will undoubtedly be a major challenge. In organ
transplantation donor organ supply is the factor that limits the
number of cases that can be performed.36, 37 In the case of facial
transplantation the donor supply carries with it unique and 
important psychosocial and ethical issues. The relationship
between facial appearance and one’s identity38 raises the question
whether families will donate facial tissues if they believe that their
deceased loved ones will be recognizable in the face of a recipient.
To address this question, we are using several approaches. First, in
the above mentioned survey we are asking individuals 
a series of questions that assess whether they think a face 
transplant recipient would look like the donor and if so, 
would they consider donating facial tissues of their loved ones
(work in progress). Secondly, we are conducting human cadaver
studies in which we transplant mask-like facial “soft tissues” from
one cadaver to the bony skeleton of another and then assess
whether the resulting soft tissue-bony skeleton combination can be
identified by independent observers (work in progress). 
Initial findings from this latter study indicates that 
recipients do not look like the donor or the recipient but rather like
a combination of the two. These preliminary findings are 
supported by others using computer generated imaging tech-
niques.39
To address the many ethical issues associated with facial tran
plantation, in 1997 our team adopted and has followed a set of 
ethical guidelines recommended in a 1988 publication by eminent
surgeon and ethicist Dr Francis Moore40 and a 1997 presentation41
and resulting publication42 by ethicist Dr Mark Siegler. Together
these publications recommend that four criteria be fulfilled when
introducing innovative surgical treatments: 1. Scientific
Background of the Innovation; as many uncertainties as possible
(see “equipoise” below) should have been clarified through well
planned scientific research; 2. Field Strength; those who 
introduce a new surgical treatment should have the skill and 
experience to perform such a procedure; 3. Ethical Climate of the
Institution; the motives of the institution should be centered on
patient care and advancement of science; 4. Open Display and
Public and Professional Discussion and Evaluation; this point is
especially relevant to this editorial. At all stages of developing 
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an innovative treatment there should be public and professional
forums for open discussion and evaluation by peers and the 
general public.  Examples of professional discussion are the 
present editorial, the Royal College of Surgeon’s Working Party
report,31 publications in scientific and clinical journals43, 44, 45, 46 and
presentations at scientific meetings.47, 48 Forums for public 
discussion on facial transplantation have been in the form of 
public gatherings,49 website based discussions50 and several forms
of lay media.  According to Moore and Siegler, if every effort has
been made to follow these four criteria when introducing surgical
innovations then clinical scientists may proceed.
The question of whether enough scientific research and 
preparation has been done to justify moving into the clinical arena
is addressed by Siegler in his description of equipoise.42 Equipoise
refers to a situation of uncertainty in which the clinical 
investigator regards the potential outcome of a clinical trial as
truly balanced between its potential for benefiting a patient and for
causing unintended harm.42 The key term here is “uncertainty.”
At stake is an uncertainty that remains at the point at which one
has gained as much knowledge as one can without actually 
performing the innovative procedure. Therefore the only way to
acquire the knowledge that is still lacking - the knowledge needed
to resolve the uncertainty - is to actually carry out the innovative
procedure in humans and see what happens.  In the case of facial
transplantation, particularly in psychological and societal issues,
we find ourselvesin a position of equipoise because we are 
destined to remain uncertain about whether the benefits will 
outweigh the harms (or vice versa) until we actually perform the
procedure in humans and follow the outcomes.
In summary, we believe that for a select population of severely
disfigured individuals facial transplantation, despite its recognized
risks, could provide a better treatment option than current 
methods. The actual surgical techniques necessary to perform 
these procedures, while technically demanding, are commonly
performed and are readily available today. From an 
immunological standpoint since face and hand contain mostly 
the same tissues it is reasonable to assume that the same 
immunosuppressive regimen found to be effective in human hand
transplants should also work in face transplantation. While there
are risks associated with these immunosuppressive drugs these
risks have been extensively studied in large populations of solid
organ transplant recipients and are well known and documented.
The ethical issues associated with the risks and benefits of 
performing an innovative procedure of this type will always be
present. To assure that facial transplantation moves into the 
clinical research phase in a thoughtful and well planned manner it
is important that teams proposing to perform this procedure 
establish and follow well defined ethical guidelines. The role of
clinical scientists is to gather as much knowledge as possible
about a new treatment from research, clinical experience, 
professional and public discussion and with this inform the patient
and his/her family as best as is possible about the associated risks
and benefits. As with all innovative medical advances ultimately 
it is the patient who must decide whether to be treated.
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Abstract
Transplantation remains one of the most discussed 
surgical specialties within the media, from both a scientific and
ethical point of view. In a lifetime transplantation has moved from
a speculative experiment to a relatively commonplace lifesaving
set of procedures.  Within medicine, transplantation offers 
interaction between some of the sickest patients and the crafts 
of surgery,clinical immunology, and various medical specialities,
as well as being the subject of huge quantities of clinical and basic
scientific research. The many high profile advances in 
transplantation in recent years have been made possible by 
some very significant developments in the armamentarium 
of immunosuppressive drugs available for combating the rejection
process.  In this article, we will briefly discuss the rejection
process and the drugs which are used to counter it.
The Rejection Process.
Rejection of solid organ transplants revolves around the CD4+ T
lymphocyte, the helper T cell. This cell is activated by the presen-
tation to it of fragments of alloantigens by antigen-presenting 
cells (APCs) on their MHC class II molecules.1,2 This interaction
of the T cell’s receptor with the MHC class II / antigen complex
leads to internal signalling within the T-cell, which then increases
the production of the cytokine, interleukin 2 (IL-2)(B). IL-2 
is responsible for on-going activation of T-cells. This activation
leads to the effector arm of the immune response being recruited
to perform the task of destroying the transplanted graft. 
The effectors include cytotoxic T lymphocytes, which act to kill
the graft directly, antibodies produced by B-lymphocytes, 
or antigen non-specific macrophages, which cause a local ‘delayed
type hypersensitivity’3 Since the helper T cell is the key 
to the generation of such immune responses all current 
immunosuppressive drugs have a role in preventing T cell 
activation, in addition to any other roles they may play.
Methods of Preventing Transplant Rejection.
Aside from the miraculous but apocryphal (St Cosmos and 
St Damian’s leg transplant), and twin-to-twin transplants, 
transplant survival generally depends upon a cocktail of various
drugs. Immunosuppression is always a balance between 
preventing rejection of a given graft and leaving the patient 
vulnerable to overwhelming infection, or other adverse effects of
the therapy, such as end organ toxicity or malignancy.4, 5, 6 
When organ transplantation first began, the immunosuppression
used consisted of two drugs used in combination, azathioprine and
corticosteroids . Up to the early 1980’s, this was really the only
available prophylaxis against the rejection process, and it was not
unsuccessful, many  units still having long-standing patients in
their care on this regimen. The introduction of the drug ciclosporin
at this time markedly improved renal allograft survival.7 At the
same time antibody therapy, with either polyclonal or monoclonal 
anti-lymphocyte antibodies was introduced.8 However, since 1995
several news drugs have been introduced, including Tacrolimus,
mycophenolate mofetil (MMF), sirolimus, and two new 
monoclonal antibodies specific for the interleukin-2 receptor.9
More recently the aim of inducing transplantation tolerance 
has crept in to the vocabulary of the transplant physician. 
Rather than simply blocking activation, it aims to manipulate the
immune system in such a way as to enable the host immune 
system to tolerate a transplant, or more specifically be 
unresponsive to the antigens from the transplant, and thus greatly
reduce the level, if any, of drugs needed to prevent rejection.10
It implies that only the T-cells and B-cells responsible for graft
recognition would be immobilised or eliminated, leaving the rest
of the T- and B- cell populations available to participate in their
normal physiological role, thus reducing vulnerability 
to opportunistic infection, as well as reducing or preventing the
adverse effects of immunosuppresents. This area of transplant
immunology is the subject of much current interest and research.
Current cellular experimental approaches include introducing
donor cells into the circulation of the recipient, thus inducing
chimerism11
From a pharmacological point of view, a number of approaches
have been considered, but it is important to realise that generating
tolerance is more than simply blocking the recognition of antigen
specific responses, but rather is an active process. As described
above, antigen recognition by T-cells leads to generation of
intracellular messages. These messages are often referred to as
“signal one”. However, when a T-cell interacts with an antigen
presenting cell (APC), several non-antigen-specific interactions
also occur, leading to a second signal “signal two”. The most
important of these are between CD80 and CD86 on the APC and
CD28 on the T-cell, and also CD40 on the APC and CD40L on
the T cell. 
A number of experimental agents (CTLA4 Ig, anti-B7 antibodies
